Sera Prognostics (SERA) Stock Price, News & Analysis

Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $6.12 to $6.57
• 50-Day Range: $6.03 to $8.74
• 52-Week Range: $1.80 to $12.35
• Volume: 33,142 shs
• Average Volume: 172,202 shs
• Market Capitalization: $220.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

SERA Stock Analysis - Frequently Asked Questions

How have SERA shares performed this year?

Sera Prognostics' stock was trading at $5.98 on January 1st, 2024. Since then, SERA stock has increased by 9.4% and is now trading at $6.54.
View the best growth stocks for 2024 here.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.09 million.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' top institutional shareholders include Geode Capital Management LLC (1.76%), State Street Corp (1.27%), Barclays PLC (0.12%) and Barclays PLC (0.12%). Insiders that own company stock include Zhenya Lindgardt, Austin Aerts, Paul Kearney, John J Boniface, Robert Gardner Harrison and Mansoor Raza Mirza.
View institutional ownership trends.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sera Prognostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/19/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:SERA
• CUSIP: N/A
• CIK: 1534969
• Web: www.seraprognostics.com
• Phone: 801-990-0520
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,240,000.00
• Net Margins: N/A
• Pretax Margin: -34,302.13%
• Return on Equity: -51.73%
• Return on Assets: -36.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $310,000.00
• Price / Sales: 712.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.62 per share
• Price / Book: 4.04

Miscellaneous

• Outstanding Shares: 33,770,000
• Free Float: 28,436,000
• Market Cap: $220.86 million
• Optionable: Optionable
• Beta: 1.04